155 related articles for article (PubMed ID: 12442917)
1. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice.
Salminen E; Hogg A; Binns D; Frydenberg M; Hicks R
Acta Oncol; 2002; 41(5):425-9. PubMed ID: 12442917
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
4. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
7. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
8. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of prostate cancer using FDG-PET].
Kanamaru H; Oyama N; Akino H; Okada K
Hinyokika Kiyo; 2000 Nov; 46(11):851-3. PubMed ID: 11193311
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
Queiroz MA; Viana P; Santos A; Bastos D; Etchebehere E; Cerri G
Clin Nucl Med; 2016 Sep; 41(9):e417-9. PubMed ID: 27276202
[TBL] [Abstract][Full Text] [Related]
11. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
12. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
13. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
14. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
15. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer.
Bucerius J; Ahmadzadehfar H; Hortling N; Joe AY; Palmedo H; Biersack HJ
Prostate Cancer Prostatic Dis; 2007; 10(3):307-10. PubMed ID: 17353915
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
17. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
18. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
19. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer.
Oyama N; Akino H; Suzuki Y; Kanamaru H; Sadato N; Yonekura Y; Okada K
Jpn J Clin Oncol; 1999 Dec; 29(12):623-9. PubMed ID: 10721945
[TBL] [Abstract][Full Text] [Related]
20. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
